Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome

Figure 2 Cumulative freedom from the risk of major adverse cardiac events during three years of follow-up. Patients classified into the second (T2) and third (T3) tertiles of the change in lipoprotein(a) [Lp(a)] circulating levels of Lp(a) after percutaneous coronary intervention for acute coronary syndrome, The changes from 0 to 12 h [Lp(a)Δ0-12], showed significantly favorable outcomes compared to those classified into the first tertile (T1) in terms of all-cause death, nonfatal myocardial infarction and stroke, or new angina pectoris (log-rank test χ² = 4.23, ^aP < 0.05). MACE: Major adverse cardiac events.